Nachrichten zur JOHNSON SVC. LS-,10 Aktie

Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Johnson & Johnson (JNJ) reached $269.12 at the closing of the latest trading day, reflecting a -2.22% change compared to…

J&Js run to record highs hasnt reached the finish line yet. Here are the key drivers

Jim Cramer agrees with UBS: The rally in Johnson & Johnson shares still has room to run.…

Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts

Johnson & Johnson (JNJ) closed at $271.19 in the latest trading session, marking a +2.01% move from the prior day.…

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.…

Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…

Warren Buffett Thinks Investors Are "Gambling" Right Now. Here are 2 Stocks That Should Be Safe Bets.

Johnson & Johnson and Merck are healthcare giants with dependable returns that weather economic downturns well.…

Johnson & Johnson Just Got a Big FDA Win

The companys autoimmune drug was approved for the treatment of a rare blood disease.…

The Zacks Analyst Blog Highlights JPMorgan, Johnson & Johnson, Mastercard and Comstock

JPMorgan leads today???s featured research, with growth drivers, strategic moves and key risks highlighted across major stocks and a microcap.…

Top Analyst Reports for JPMorgan, Johnson & Johnson & Mastercard

JPMorgan, Johnson & Johnson and Mastercard headline todays research, with growth drivers and key risks shaping each stocks outlook.…

Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $270.27, denoting a -1.05% move from…

Q2 Earnings Season Winds Down: 3 Companies That Broke Records

The 2026 Q2 earnings cycle continues to wind down, with the reporting docket starting to get quiet. The period has…

Better Dividend King to Buy Right Now: Abbott Labs or Johnson & Johnson?

These two high-quality dividend payers have had very different fortunes recently.…

Johnson & Johnson: Buy IMAAVY Label Expansion First And Continued CAPLYTA Sales Push

…

ACHV: Looking Ahead to Resubmission

By John Vandermosten, CFANASDAQ: ACHVREAD THE FULL ACHV RESEARCH REPORTAchieve Life Sciences, Inc. (NASDAQ: ACHV) reported second quarter results, introducing…

Why Is Johnson & Johnson (JNJ) Up 4.8% Since Last Earnings Report?

Johnson & Johnson (JNJ) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings…

This Dividend Aristocrat Posted Record Quarterly Results

Johnson & Johnson shares have quietly delivered a huge gain in 2026 so far, up more than 25%. The gain…

Jim Cramer Analyzes Johnson & Johnson (JNJ) After Surgical Robotics Milestone

Jim Cramer celebrated a dramatic pivot in market sentiment surrounding Johnson & Johnson (NYSE:JNJ) during Mad Money’s July 23 episode.…

Explainer: Can J&J finally put the talc litigation behind it?

After years of failed attempts to resolve thousands of lawsuits alleging that its talc products caused cancer, Johnson & Johnson…

Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth

Johnson & Johnsons revenue has grown modestly while Eli Lillys revenue has nearly doubled in two years, narrowing a once-wide…

J&J-Aktie gefragt: Johnson & Johnson will Talkum-Klagen mit milliardenschwerem Vergleich beilegen

Der US-Pharmakonzern will 5,5 Milliarden US-Dollar zur Beilegung der Klagen bereitstellen. Johnson & Johnson hatte bereits tags zuvor die Konditionen…

Rechtsstreit endet mit Vergleich: Krebserregendes Babypuder? US-Firma zahlt Milliarden

Etliche Klägerinnen werfen Johnson & Johnson vor, durch die Verwendung seiner talkumbasierten Babypuder-Produkte an Eierstockkrebs erkrankt zu sein. Der US-Pharmakonzern…

Stocks making the biggest moves premarket: Coca-Cola, Sherwin-Williams, Johnson & Johnson & more

These are the stocks posting the largest moves in early trading.…

Johnson & Johnson proposes $5.5B settlement to resolve remaining talc litigation

Johnson & Johnson (NYSE:JNJ) has reached an agreement to resolve tens of thousands of lawsuits in the US alleging that…

Johnson & Johnson will 5,5-Milliarden-Vergleich in Babypuder-Prozessen

War Babypuder von Johnson & Johnson krebserregend? Dazu gibt es seit Jahren eine Klagewelle. Der Konzern will diese nun mit…

These 3 Companies Reported Record Results and Raised Guidance

Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson have all delivered strong earnings releases in the Q2 cycle, with each…

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Johnson & Johnson ?said on Monday it has reached ?a $5.5 billion settlement that will resolve tens of thousands of…

Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?

Both have very promising futures.…

Insider trades: Johnson & Johnson, TSMC among notable names

…

Johnson & Johnsons robotic surgery device gets US FDA marketing authorization

Johnson & Johnson said on Wednesday the U.S. ?Food and Drug Administration had granted marketing authorization for its robotic surgery…

Top Analyst Reports for Johnson & Johnson, Lam Research & Seagate

Johnson & Johnson beat Q2 estimates as growth in key drugs, MedTech and its pipeline helps offset Stelara headwinds. Read…

Johnson & Johnson Aktie: Pharma wächst, MedTech bremst

Wien (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse der Raiffeisen Bank International AG (RBI):Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI),…

ASML erhöht Gesamtjahresausblick - Apple mit starken iPhone-Verkaufszahlen - PayPal-Aktie im Aufwind

Wien (www.aktiencheck.de) - ASML (0%) konnte gestern die Umsatz- und Gewinnerwartungen für das zweite Quartal 2026 übertreffen, so die Analysten…

+++ Geschäftszahlen +++: Johnson & Johnson hebt Jahresziele an

Börsenrallye und ETF-Boom bescheren BlackRock Rekordergebnis +++ BASF hebt nach Gewinnsprung Jahresziele an Chipausrüster ASML steigert Umsatz +++ Der Newsblog.…

Is Johnson & Johnson a Buy After Its Latest Earnings Report?

Investors didnt seem to think so after the company published it.…

Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat

Johnson & Johnson raises its 2026 outlook after Q2 earnings and revenues beat estimates, driven by Innovative Medicine strength and…

Johnson & Johnson Q2-Zahlen: Ausblick erneut leicht angehoben

Wien (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse der Raiffeisen Bank International AG (RBI):Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI),…

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Johnson & ?Johnson also increased its full-year sales and ?profit ?forecast.…

Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidance

Johnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as strong pharmaceutical sales...…

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Johnson & Johnson beat Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from immunology drug…

Tech Futures Rise With Nasdaq At Key Level; Oil Pushes Above $80

ASML, Johnson & Johnson, PayPal lead early movers on news.…

Johnson & Johnson Aktie: Wachsende Zuversicht

Toronto (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von RBC Capital Markets:RBC Capital habe das Kursziel für die Aktie von Johnson &…

Is Johnson & Johnson Stock Poised for New Highs as Q2 Results Approach?

After hitting fresh all-time highs last week, investors are turning their attention to JNJs Q2 report, which is scheduled for…

Q2 Earnings Season Arrives: Can Results Match Upbeat Expectations?

The big banks dominate this weeks reporting docket, though several notable companies from other sectors will also report, including Netflix,…

Johnson Service backs outlook despite hospitality weakness

Johnson Service Group plc (LSE:JSG) said it remained on track to deliver its 2026 margin target despite continued weakness in…

Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key…

Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors

Johnson & Johnson (JNJ) closed at $263.4 in the latest trading session, marking a -1.44% move from the prior day.…

Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…

Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?

Johnson & Johnson doesnt need GLP-1 drugs to grow, and thats good news for long-term investors.…

[Latest] Global Gauze Bandage Rolls Market Size/Share Worth USD 3.19 Billion by 2035 at a 4.97% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Gauze…

Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Bristol Myers Squibb trades at a deep discount, while Johnson & Johnson boasts higher margins and a broader reach. How…